[Ca²⁺-activated K⁺ channels as cancer therapeutic targets]

Area of Science:

• Oncology
• Molecular Biology
• Ion Channel Physiology

Background:

• Potassium (K+) channels, like calcium (Ca2+) and chloride channels, are critical targets for cancer therapy.
• Elevated expression of Ca2+-activated K+ (KCa) channels correlates with increased cancer proliferation, metastasis, and poor prognosis.
• KCa1.1 and KCa3.1 channels form a positive-feedback loop with Ca2+ channels in cancer cells, promoting growth and metastasis.

Purpose of the Study:

• To investigate the epigenetic and post-transcriptional regulation of KCa3.1 channels in breast and prostate cancer cells.
• To explore the therapeutic potential of targeting KCa1.1 channels in triple-negative breast cancer.
• To evaluate KCa3.1 activators as a strategy to counteract the tumor-promoting effects of interleukin-10 (IL-10).

Main Methods:

• Utilized class I histone deacetylase inhibitors to study KCa3.1 dysregulation.
• Investigated vitamin D receptor agonists and androgen receptor antagonists for KCa1.1 regulation.
• Assessed the impact of KCa3.1 activators on IL-10-mediated tumor-promoting activities.

Main Results:

• Epigenetic and post-transcriptional dysregulation of KCa3.1 was observed in response to histone deacetylase inhibitors.
• Vitamin D receptor agonists and androgen receptor antagonists demonstrated potential for transcriptional repression and protein degradation of KCa1.1.
• KCa3.1 activators were identified as a potential therapeutic approach to inhibit IL-10's pro-tumorigenic functions.

Conclusions:

• KCa3.1 and KCa1.1 channels represent significant therapeutic targets and biomarkers in various cancers.
• Targeting these channels with specific pharmacological agents offers novel treatment strategies for breast and prostate cancers.
• Modulating KCa channel activity provides new insights for developing targeted cancer therapies.